Olema Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-6.4%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$2.42next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| OPERA-01 Phase 3 Monotherapy Top-line Data Release | 15 Oct 2026 |
| Q3 2026 Financial Results and Operational Update | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
OPERA-01 Phase 3 Trial Top-line Data Readout AnnuallyTarget: Top-line data readout expected in Fall 2026
OPERA-02 Phase 3 Trial Enrollment and Progress QuarterlyTarget: Continued global patient enrollment with top-line data anticipated in 2028
OP-3136 Phase 1 Clinical Trial Advancement QuarterlyTarget: Progressing dose escalation/expansion and initiating combination cohorts with palazestrant
Cash Runway Maintenance Quarterly505.3MTarget: Maintain sufficient liquidity to fund operations through mid-2028
Watch Items
- OPERA-01 Phase 3 Monotherapy Top-line DataTrigger: Efficacy (PFS) and safety profile comparison vs. standard-of-care endocrine therapyAction: Prepare NDA submission for monotherapy in 2027 if successful; re-evaluate clinical strategy if trial fails to meet primary endpoint
- OP-3136 KAT6 Inhibitor Combination CohortsTrigger: Initial safety and efficacy signals of OP-3136 in combination with palazestrant or fulvestrantAction: Determine optimal Phase 2 combination dose and advance clinical development plans in metastatic breast cancer
- Bayer Collaboration for OP-3136 in Prostate CancerTrigger: Initiation of clinical evaluation of OP-3136 in combination with NUBEQA (darolutamide) in mCRPCAction: Monitor trial progress and evaluate expansion of the KAT6 inhibitor platform into non-breast cancer indications
Research as of 20 Jun 2026